La cadena de opciones muestra datos clave de las opciones de acciones de Torrid Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Torrid Holdings..

Torrid Holdings (NYSE:CURV) Bolsa, Cadena de Opciones

TORRID HOLDINGS INC

Torrid Holdings

Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.

Torrid Holdings Inc

Curve DAO Token - United States Dollar

CurveBeam AI Ltd

CURVES HLDGS CO LTD by CURVES HLDGS CO LTD.

Curves Holdings Co Ltd

Piper Sandler analyst Brent Bracelin maintains Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) with a Overweight and raises the price target from $14 to $15.

News

Price Target

Analyst Ratings

WEAV

Piper Sandler Maintains Overweight on Weave Communications, Raises Price Target to $15

Jacobs Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) shares edged lower on Tuesday after the company reported <a href="https://www.benzinga.com/pressreleases/25/05/n45216538/jacobs-reports-strong-fiscal-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">second-quarter 2025</a> results. Revenue rose 2.2% year-over-year to $2.91 billion, topping the $2.18 billion consensus.
Adjusted revenue grew 3.1% year-over-year to $2.14 billion. Adjusted EPS was $1.43, up from $1.17 a year ago, above the consensus of $1.39.
Gross margin was at 25.4% YoY, up 36 bps, and gross profit rose 3.7% to $738.35 million. Operating margin expanded 73 bps to 7.2% YoY, and operating profit rose 13.9% to $208.65 million.
Jacobs reported a $109.5 million mark-to-market loss on the AMTM investment, lowering the quarter&#8217;s GAAP net income.
The quarterly backlog reached $22.2 billion, up 20% year-over-year, with a book-to-bill ratio of 1.1x (1.3x on a trailing twelve-month basis).
Operating cash used in operating activities for the quarter totaled $96.43 million, compared to $42.82 million a year ago.
The company delivered record capital returns to shareholders in the first half of the year, repurchasing $351 million in shares during the second quarter and $552 million over the first half.
Jacobs&#8217; Chair and CEO Bob Pragada said, &#8220;We ended the first half of FY25 with solid performance across our business, led by strong Life Sciences, Transportation, and Energy &amp; Power revenue growth within Infrastructure &amp; Advanced Facilities (I&amp;AF). Additionally, we saw strong results in PA Consulting, with revenue growth rising to 5% in the second quarter, driving 12% operating profit growth for the segment. As we look ahead to the second half of the fiscal year, we continue to see tailwinds in both segments from robust bookings and a healthy pipeline of opportunities across our end markets. Based on this performance, we are reaffirming our full-year fiscal 2025 guidance.&#8221;
The company also retired $312 million in debt through an equity-for-debt exchange using its stake in AMTM and refinanced approximately $700 million of existing debt at a lower interest rate, significantly strengthening its balance sheet exiting Q2 2025.
Pragada added, &#8220;Following the quarter&#8217;s close, we reached a key milestone in separating the former CMS and C&amp;I businesses by finalizing the post-closing working capital adjustment, enabling additional debt reduction in Q3 2025, and receiving Board approval to distribute the remaining Amentum shares to our shareholders on May 30th.&#8221;
2025 Outlook reaffirmed: Jacobs sees adjusted net revenue growing mid-to-high single digits, with an EBITDA margin of 13.8-14.0% and FCF conversion exceeding 100% of net income.
The company expects adjusted EPS of $5.85 – $6.20 (versus the $6.03 consensus) for 2025.
Price Action: J shares are trading lower by 4.76% at $120.52 on Tuesday&#8217;s last check.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45228066/amds-recovery-from-62-value-wipeout-faces-q1-earnings-test-can-it-break-long-term-resistance">AMD Recovers From 62% Value Wipeout, Faces Q1 Earnings Test: Can It Break Long-Term Resistance?</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Jacobs Delivers Mixed Q2: Revenue Tops, Guidance Held, AMTM Loss Weighs On Results

Piper Sandler analyst Thomas Champion reiterates Vimeo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) with a Overweight and lowers the price target from $10 to $8.

Reiteration

VMEO

Piper Sandler Reiterates Overweight on Vimeo, Lowers Price Target to $8

Accenture Acquires Ascendient Learning, Subsidiary Of Axcel Learning, From Alpine Investors; Terms Not Disclosed

Monness, Crespi, Hardt analyst Gus Gala downgrades Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from Buy to Neutral.

Downgrades

COIN

Monness, Crespi, Hardt Downgrades Coinbase Global to Neutral

<a href="https://www.youtube.com/watch?v=CuRS6FT95qc" title="https://www.youtube.com/watch?v=CuRS6FT95qc">https://www.youtube.com/watch?v=CuRS6FT95qc</a>

Macro Economic Events

Politics

Global

Economics

General

President Trump Says We Will Possibly Start To Renegotiate USMCA

Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) has outperformed the market over the past 5 years by 6.18% on an annualized basis producing an average annual return of 20.07%. Currently, Baker Hughes has a market capitalization of $36.38 billion. 
Buying $100 In BKR: If an investor had bought $100 of BKR stock 5 years ago, it would be worth $243.07 today based on a price of $36.72 for BKR at the time of writing.
<h3>Baker Hughes's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746548116_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Piper Sandler analyst Alexander Potter maintains Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) with a Neutral and lowers the price target from $9 to $8.5.

Piper Sandler Maintains Neutral on Ford Motor, Lowers Price Target to $8.5

Trump Meets With Newly-Elected Canadian PM Mark Carney; President Trump Says We Will Have A Very Big Announcement Before Middle East Trip; Really Positive Announcement Thursday, Friday Or Monday Before We Leave

Piper Sandler analyst David Westenberg maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral and raises the price target from $260 to $280.

Laboratory Corporation Of America Holdings

Piper Sandler Maintains Neutral on Labcorp Hldgs, Raises Price Target to $280

<a href="https://www.eia.gov/outlooks/steo/" title="https://www.eia.gov/outlooks/steo/">https://www.eia.gov/outlooks/steo/</a>

Econ #s

EIA Sees 2025 U.S. Natgas Output Of 104.9 BCF/Day, Vs Prior Forecast 105.3 BCF/Day; Sees 2026 Demand Of 106.4 BCF/Day; Sees 2025 U.S. Oil Demand Of 20.5M Barrels/Day, Vs Prior Forecast 20.4M Barrels/Day; Sees 2026 Demand Of 20.4M Barrels/Day; Sees 2025 U.S. Natgas Demand Of 91.3 BCF/Day, Vs Prior Forecast 91.2 BCF/Day; Sees 2026 Demand Of 90.7 BCF/Day

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $420 to $423.

VRTX

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $423

EIA Says U.S. Oil Production To Average 13.37M Barrels/Day In May Vs 13.33M Barrels/Day In April; To Average 13.4M Barrels/Day In June; Natural Gas Production To Average 115.2 BCF/day In May Vs 115.5 BCF/Day In April; To Average 115.8 BCF/Day In June; Sees 2025 U.S. Oil Output Of 13.42M Barrels/Day, Vs Prior Forecast 13.51M Barrels/Day; Sees 2026 Output Of 13.49M Barrels/Day

Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Overweight and lowers the price target from $18 to $12.

Piper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $12

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) with a Overweight and raises the price target from $50 to $60.

Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $60

WIIM

CRBP

Corbus Pharmaceuticals Holdings shares are trading lower. The company reported Q1 financial results.

Scotiabank analyst Ben Isaacson maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Sector Perform and lowers the price target from $75 to $65.

Scotiabank Maintains Sector Perform on Albemarle, Lowers Price Target to $65

RBC Capital analyst Brad Erickson reiterates Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Sector Perform and maintains $18 price target.

UPWK

RBC Capital Reiterates Sector Perform on Upwork, Maintains $18 Price Target

Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) with a Neutral and raises the price target from $16 to $23.

FLGT

Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $23

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $11 to $13.

ADPT

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $13

Legal

Press Releases

CURV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Torrid Holdings Inc. and Encourages Investors to Contact the Firm!

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Torrid Holdings Inc. - CURV

Torrid Announces Reporting Date for Third Quarter Fiscal 2024 Financial Results

Torrid Reports Third Quarter Fiscal 2024 Results

Torrid Announces Participation in the 27th Annual ICR Conference

Small Cap

The Law Offices of Frank R. Cruz Announces Investigation of Torrid Holdings Inc. (CURV) on Behalf of Investors

Torrid Announces Reporting Date for Fourth Quarter and Fiscal 2024 Financial Results

Torrid Reports Fourth Quarter and Fiscal 2024 Results and Initiates Fiscal 2025 Guidance

CURV

American Eagle Outfitters, Inc. Common Stock

American Eagle Outfitters

Abercrombie & Fitch

Buckle

Boot Barn Holdings

Burlington Stores

Caleres

Citi Trends

Designer Brands Inc. Class A Common Stock

Designer Brands

Foot Locker

Genesco

Guess

J.Jill

Lands' End

LuxExperience B.V. American Depositary Shares, each representing one Ordinary Share

Comments

Torrid Holdings

Torrid Holdings (CURV) Opciones

Torrid Holdings (NYSE:CURV) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL